The global Autoimmune Disease Drugs market size was valued at US$ 146420 million in 2024 and is forecast to a readjusted size of USD 186630 million by 2031 with a CAGR of 3.5% during review period.
Autoimmune Disease Drugs refer to a class of drugs used to treat autoimmune diseases that are caused by the immune system mistakenly attacking the body's own tissues. These drugs are designed to regulate or suppress an overactive immune response to reduce symptoms, slow disease progression, and help patients maintain a normal quality of life. Common autoimmune disease drugs include anti-inflammatory drugs, immunosuppressants, biologics, etc., which act on the immune system through different mechanisms to control the condition and reduce damage to the body.
This report is a detailed and comprehensive analysis for global Autoimmune Disease Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Autoimmune Disease Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Autoimmune Disease Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Autoimmune Disease Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Autoimmune Disease Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Autoimmune Disease Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Autoimmune Disease Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Qyuns Therapeutics, Bio-Thera Solutions, Hengrui Pharmaceuticals, Hisun Pharmaceutical, Sunshine Guojian Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Chongqing Genrix Biopharmaceutical, Keymed Biosciences, Junshi Biosciences, Akeso, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Autoimmune Disease Drugs market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Biopharma
Small Molecule Drug
麻豆原创 segment by Application
Hospital
Clinic
Others
Major players covered
Qyuns Therapeutics
Bio-Thera Solutions
Hengrui Pharmaceuticals
Hisun Pharmaceutical
Sunshine Guojian Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Chongqing Genrix Biopharmaceutical
Keymed Biosciences
Junshi Biosciences
Akeso
AbbVie
AstraZeneca
Biogen
Bristol Myers Squibb
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis AG
Pfizer
Roche Holding
Sanofi S.A.
Takeda Pharmaceutical
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Autoimmune Disease Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Autoimmune Disease Drugs, with price, sales quantity, revenue, and global market share of Autoimmune Disease Drugs from 2020 to 2025.
Chapter 3, the Autoimmune Disease Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Autoimmune Disease Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Autoimmune Disease Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Autoimmune Disease Drugs.
Chapter 14 and 15, to describe Autoimmune Disease Drugs sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Autoimmune Disease Drugs Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Biopharma
1.3.3 Small Molecule Drug
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Autoimmune Disease Drugs Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Autoimmune Disease Drugs 麻豆原创 Size & Forecast
1.5.1 Global Autoimmune Disease Drugs Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Autoimmune Disease Drugs Sales Quantity (2020-2031)
1.5.3 Global Autoimmune Disease Drugs Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Qyuns Therapeutics
2.1.1 Qyuns Therapeutics Details
2.1.2 Qyuns Therapeutics Major Business
2.1.3 Qyuns Therapeutics Autoimmune Disease Drugs Product and Services
2.1.4 Qyuns Therapeutics Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Qyuns Therapeutics Recent Developments/Updates
2.2 Bio-Thera Solutions
2.2.1 Bio-Thera Solutions Details
2.2.2 Bio-Thera Solutions Major Business
2.2.3 Bio-Thera Solutions Autoimmune Disease Drugs Product and Services
2.2.4 Bio-Thera Solutions Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Bio-Thera Solutions Recent Developments/Updates
2.3 Hengrui Pharmaceuticals
2.3.1 Hengrui Pharmaceuticals Details
2.3.2 Hengrui Pharmaceuticals Major Business
2.3.3 Hengrui Pharmaceuticals Autoimmune Disease Drugs Product and Services
2.3.4 Hengrui Pharmaceuticals Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Hengrui Pharmaceuticals Recent Developments/Updates
2.4 Hisun Pharmaceutical
2.4.1 Hisun Pharmaceutical Details
2.4.2 Hisun Pharmaceutical Major Business
2.4.3 Hisun Pharmaceutical Autoimmune Disease Drugs Product and Services
2.4.4 Hisun Pharmaceutical Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Hisun Pharmaceutical Recent Developments/Updates
2.5 Sunshine Guojian Pharmaceutical
2.5.1 Sunshine Guojian Pharmaceutical Details
2.5.2 Sunshine Guojian Pharmaceutical Major Business
2.5.3 Sunshine Guojian Pharmaceutical Autoimmune Disease Drugs Product and Services
2.5.4 Sunshine Guojian Pharmaceutical Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Sunshine Guojian Pharmaceutical Recent Developments/Updates
2.6 Chia Tai Tianqing Pharmaceutical
2.6.1 Chia Tai Tianqing Pharmaceutical Details
2.6.2 Chia Tai Tianqing Pharmaceutical Major Business
2.6.3 Chia Tai Tianqing Pharmaceutical Autoimmune Disease Drugs Product and Services
2.6.4 Chia Tai Tianqing Pharmaceutical Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
2.7 Chongqing Genrix Biopharmaceutical
2.7.1 Chongqing Genrix Biopharmaceutical Details
2.7.2 Chongqing Genrix Biopharmaceutical Major Business
2.7.3 Chongqing Genrix Biopharmaceutical Autoimmune Disease Drugs Product and Services
2.7.4 Chongqing Genrix Biopharmaceutical Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Chongqing Genrix Biopharmaceutical Recent Developments/Updates
2.8 Keymed Biosciences
2.8.1 Keymed Biosciences Details
2.8.2 Keymed Biosciences Major Business
2.8.3 Keymed Biosciences Autoimmune Disease Drugs Product and Services
2.8.4 Keymed Biosciences Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Keymed Biosciences Recent Developments/Updates
2.9 Junshi Biosciences
2.9.1 Junshi Biosciences Details
2.9.2 Junshi Biosciences Major Business
2.9.3 Junshi Biosciences Autoimmune Disease Drugs Product and Services
2.9.4 Junshi Biosciences Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Junshi Biosciences Recent Developments/Updates
2.10 Akeso
2.10.1 Akeso Details
2.10.2 Akeso Major Business
2.10.3 Akeso Autoimmune Disease Drugs Product and Services
2.10.4 Akeso Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Akeso Recent Developments/Updates
2.11 AbbVie
2.11.1 AbbVie Details
2.11.2 AbbVie Major Business
2.11.3 AbbVie Autoimmune Disease Drugs Product and Services
2.11.4 AbbVie Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 AbbVie Recent Developments/Updates
2.12 AstraZeneca
2.12.1 AstraZeneca Details
2.12.2 AstraZeneca Major Business
2.12.3 AstraZeneca Autoimmune Disease Drugs Product and Services
2.12.4 AstraZeneca Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 AstraZeneca Recent Developments/Updates
2.13 Biogen
2.13.1 Biogen Details
2.13.2 Biogen Major Business
2.13.3 Biogen Autoimmune Disease Drugs Product and Services
2.13.4 Biogen Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Biogen Recent Developments/Updates
2.14 Bristol Myers Squibb
2.14.1 Bristol Myers Squibb Details
2.14.2 Bristol Myers Squibb Major Business
2.14.3 Bristol Myers Squibb Autoimmune Disease Drugs Product and Services
2.14.4 Bristol Myers Squibb Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Bristol Myers Squibb Recent Developments/Updates
2.15 Eli Lilly
2.15.1 Eli Lilly Details
2.15.2 Eli Lilly Major Business
2.15.3 Eli Lilly Autoimmune Disease Drugs Product and Services
2.15.4 Eli Lilly Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Eli Lilly Recent Developments/Updates
2.16 GlaxoSmithKline
2.16.1 GlaxoSmithKline Details
2.16.2 GlaxoSmithKline Major Business
2.16.3 GlaxoSmithKline Autoimmune Disease Drugs Product and Services
2.16.4 GlaxoSmithKline Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 GlaxoSmithKline Recent Developments/Updates
2.17 Johnson & Johnson
2.17.1 Johnson & Johnson Details
2.17.2 Johnson & Johnson Major Business
2.17.3 Johnson & Johnson Autoimmune Disease Drugs Product and Services
2.17.4 Johnson & Johnson Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Johnson & Johnson Recent Developments/Updates
2.18 Merck
2.18.1 Merck Details
2.18.2 Merck Major Business
2.18.3 Merck Autoimmune Disease Drugs Product and Services
2.18.4 Merck Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Merck Recent Developments/Updates
2.19 Novartis AG
2.19.1 Novartis AG Details
2.19.2 Novartis AG Major Business
2.19.3 Novartis AG Autoimmune Disease Drugs Product and Services
2.19.4 Novartis AG Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 Novartis AG Recent Developments/Updates
2.20 Pfizer
2.20.1 Pfizer Details
2.20.2 Pfizer Major Business
2.20.3 Pfizer Autoimmune Disease Drugs Product and Services
2.20.4 Pfizer Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 Pfizer Recent Developments/Updates
2.21 Roche Holding
2.21.1 Roche Holding Details
2.21.2 Roche Holding Major Business
2.21.3 Roche Holding Autoimmune Disease Drugs Product and Services
2.21.4 Roche Holding Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.21.5 Roche Holding Recent Developments/Updates
2.22 Sanofi S.A.
2.22.1 Sanofi S.A. Details
2.22.2 Sanofi S.A. Major Business
2.22.3 Sanofi S.A. Autoimmune Disease Drugs Product and Services
2.22.4 Sanofi S.A. Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.22.5 Sanofi S.A. Recent Developments/Updates
2.23 Takeda Pharmaceutical
2.23.1 Takeda Pharmaceutical Details
2.23.2 Takeda Pharmaceutical Major Business
2.23.3 Takeda Pharmaceutical Autoimmune Disease Drugs Product and Services
2.23.4 Takeda Pharmaceutical Autoimmune Disease Drugs Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.23.5 Takeda Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Autoimmune Disease Drugs by Manufacturer
3.1 Global Autoimmune Disease Drugs Sales Quantity by Manufacturer (2020-2025)
3.2 Global Autoimmune Disease Drugs Revenue by Manufacturer (2020-2025)
3.3 Global Autoimmune Disease Drugs Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Autoimmune Disease Drugs by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Autoimmune Disease Drugs Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Autoimmune Disease Drugs Manufacturer 麻豆原创 Share in 2024
3.5 Autoimmune Disease Drugs 麻豆原创: Overall Company Footprint Analysis
3.5.1 Autoimmune Disease Drugs 麻豆原创: Region Footprint
3.5.2 Autoimmune Disease Drugs 麻豆原创: Company Product Type Footprint
3.5.3 Autoimmune Disease Drugs 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Autoimmune Disease Drugs 麻豆原创 Size by Region
4.1.1 Global Autoimmune Disease Drugs Sales Quantity by Region (2020-2031)
4.1.2 Global Autoimmune Disease Drugs Consumption Value by Region (2020-2031)
4.1.3 Global Autoimmune Disease Drugs Average Price by Region (2020-2031)
4.2 North America Autoimmune Disease Drugs Consumption Value (2020-2031)
4.3 Europe Autoimmune Disease Drugs Consumption Value (2020-2031)
4.4 Asia-Pacific Autoimmune Disease Drugs Consumption Value (2020-2031)
4.5 South America Autoimmune Disease Drugs Consumption Value (2020-2031)
4.6 Middle East & Africa Autoimmune Disease Drugs Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Autoimmune Disease Drugs Sales Quantity by Type (2020-2031)
5.2 Global Autoimmune Disease Drugs Consumption Value by Type (2020-2031)
5.3 Global Autoimmune Disease Drugs Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Autoimmune Disease Drugs Sales Quantity by Application (2020-2031)
6.2 Global Autoimmune Disease Drugs Consumption Value by Application (2020-2031)
6.3 Global Autoimmune Disease Drugs Average Price by Application (2020-2031)
7 North America
7.1 North America Autoimmune Disease Drugs Sales Quantity by Type (2020-2031)
7.2 North America Autoimmune Disease Drugs Sales Quantity by Application (2020-2031)
7.3 North America Autoimmune Disease Drugs 麻豆原创 Size by Country
7.3.1 North America Autoimmune Disease Drugs Sales Quantity by Country (2020-2031)
7.3.2 North America Autoimmune Disease Drugs Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Autoimmune Disease Drugs Sales Quantity by Type (2020-2031)
8.2 Europe Autoimmune Disease Drugs Sales Quantity by Application (2020-2031)
8.3 Europe Autoimmune Disease Drugs 麻豆原创 Size by Country
8.3.1 Europe Autoimmune Disease Drugs Sales Quantity by Country (2020-2031)
8.3.2 Europe Autoimmune Disease Drugs Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Autoimmune Disease Drugs Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Autoimmune Disease Drugs Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Autoimmune Disease Drugs 麻豆原创 Size by Region
9.3.1 Asia-Pacific Autoimmune Disease Drugs Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Autoimmune Disease Drugs Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Autoimmune Disease Drugs Sales Quantity by Type (2020-2031)
10.2 South America Autoimmune Disease Drugs Sales Quantity by Application (2020-2031)
10.3 South America Autoimmune Disease Drugs 麻豆原创 Size by Country
10.3.1 South America Autoimmune Disease Drugs Sales Quantity by Country (2020-2031)
10.3.2 South America Autoimmune Disease Drugs Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Autoimmune Disease Drugs Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Autoimmune Disease Drugs Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Autoimmune Disease Drugs 麻豆原创 Size by Country
11.3.1 Middle East & Africa Autoimmune Disease Drugs Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Autoimmune Disease Drugs Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Autoimmune Disease Drugs 麻豆原创 Drivers
12.2 Autoimmune Disease Drugs 麻豆原创 Restraints
12.3 Autoimmune Disease Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Autoimmune Disease Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Autoimmune Disease Drugs
13.3 Autoimmune Disease Drugs Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Autoimmune Disease Drugs Typical Distributors
14.3 Autoimmune Disease Drugs Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Qyuns Therapeutics
Bio-Thera Solutions
Hengrui Pharmaceuticals
Hisun Pharmaceutical
Sunshine Guojian Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Chongqing Genrix Biopharmaceutical
Keymed Biosciences
Junshi Biosciences
Akeso
AbbVie
AstraZeneca
Biogen
Bristol Myers Squibb
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis AG
Pfizer
Roche Holding
Sanofi S.A.
Takeda Pharmaceutical
听
听
*If Applicable.
